Division of Investigational Cancer Therapeutics
-
Supplemental Data for A Phase II Study of Talazoparib Tosylate in Advanced Cancer Patients with Somatic and Germline (Not Breast or Ovarian Cancer) Alterations of BRCA1/2, Mutations/Deletions/Amplification in Other Homologous Recombination Repair Pathway Genes and PTEN or PTEN loss
Sarina A. Piha-Paul, Chieh Tseng, Cheuk Hong Leung, Ying Yuan, Daniel D. Karp, Vivek Subbiah, David Hong, Siqing Fu, Aung Naing, Jordi Rodon, Milind Javle, Jaffer Ajani, Kanwal Raghav, Neeta Somaiah, Gordon B. Mills, Apostolia Tsimberidou, Xiaofeng Zheng, Ken Chen, and Funda Meric-Bernstam
The de-identified participant data and dataset generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Custom code that was used in the generation or analysis of the datasets is available upon reasonable request.
Corresponding Author: Sarina Piha-Paul,Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX. Phone: (713)-563-1055, Fax:(713)-792-3535, spihapau@mdanderson.org.
